Role of PKPD Modeling and Simulation in Influencing ... - Pharsight
Role of PKPD Modeling and Simulation in Influencing ... - Pharsight
Role of PKPD Modeling and Simulation in Influencing ... - Pharsight
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Event Probability (%)<br />
0 10 20 30 40 50 60 70<br />
Case Study 1: Transition<strong>in</strong>g from Precl<strong>in</strong>ical to FIH<br />
Comparison across drugs showed favorable projected response pr<strong>of</strong>ile<br />
for CS-3030, comparable to observed responses for comparator drugs.<br />
QD regimen, VTE, Hip<br />
BID regimen, VTE, Hip<br />
QD regimen, Bleed, Hip<br />
BID regimen, Bleed, Hip<br />
Warfar<strong>in</strong> (INR=2.5), VTE, Hip<br />
Warfar<strong>in</strong> (INR=2.5), Bleed, Hip<br />
0.75 1.5 2.5 3 6 8 0 10 40 60 10 20 40<br />
Fondapar<strong>in</strong>ux Dose Enoxapar<strong>in</strong> Dose CS3030 Dose<br />
(mg/day) (mg/day) (mg/day)<br />
S Rohatagi et al., Model based development <strong>of</strong> a direct Factor Xa <strong>in</strong>hibitor, ACoP Meet<strong>in</strong>g, Tucson AZ, Mar 2008<br />
Slide 23<br />
© Tripos, L.P. 2011 All Rights Reserved
Change language